| [1] |
彭代智，刘小玲，刘智勇，等. 烧伤患者2748株病原菌分布特点及耐药性分析[J]. 中华烧伤杂志，2012, 28(2): 87-95.
|
| [2] |
胡泉，柴家科，尹靓，等. 危重烧伤患者呼吸道细菌感染及耐药性分析[J/CD]. 中华损伤与修复杂志：电子版，2012, 7(1): 76-79.
|
| [3] |
黄晓元. 加强创面感染的防治[J/CD]. 中华损伤与修复杂志：电子版，2015, 10(5): 376-379.
|
| [4] |
Wang G, Li X, Wang Z. APD2: the updated antimicrobial peptide database and its application in peptide design[J]. Nucleic Acids Res, 2009, 37(Database issue): D933-D937.
|
| [5] |
Eckert R. Road to clinical efficacy: challenges and novel strategies for antimicrobial peptide development[J]. Future Microbiol, 2011, 6(6): 635-651.
|
| [6] |
Gaspar D, Veiga AS, Castanho MA. From antimicrobial to anticancer peptides. A review[J]. Front Microbiol, 2013，4: 294.
|
| [7] |
Peters BM, Shirtliff ME, Jabra-Rizk MA. Antimicrobial peptides: primeval molecules or future drugs [J]. PLoS Pathog, 2010, 6(10): e1001067.
|
| [8] |
Steckbeck JD, Deslouches B, Montelaro RC. Antimicrobial peptides: new drugs for bad bugs [J]. Expert Opin Biol Ther, 2014, 14(1): 11-14.
|
| [9] |
Baltzer SA, Brown MH. Antimicrobial peptides: promising alternatives to conventional antibiotics[J]. J Mol Microbiol Biotechnol, 2011, 20(4): 228-235.
|
| [10] |
Hancock RE, Nijnik A, Philpott DJ. Modulating immunity as a therapy for bacterial infections[J]. Nat Rev Microbiol, 2012, 10(4): 243-254.
|
| [11] |
Mookherjee N, Hancock RE. Cationic host defence peptides: innate immune regulatory peptides as a novel approach for treating infections[J]. Cell Mol Life Sci, 2007, 64(7/8): 922-933.
|
| [12] |
史鹏伟，高艳彬，卢志阳，等. 抗菌肽LL-37对鲍曼不动杆菌生物膜的抑制作用[J]. 南方医科大学学报，2014, 34(3): 426-429.
|
| [13] |
Reffuveille F, de la Fuente-Núñez C, Mansour S, et al. A broad-spectrum antibiofilm peptide enhances antibiotic action against bacterial biofilms[J]. Antimicrob Agents Chemother, 2014, 58(9): 5363-5371.
|
| [14] |
Mercer DK, O′Neil DA. Peptides as the next generation of anti-infectives[J]. Future Med Chem, 2013, 5(3): 315-337.
|
| [15] |
Lipsky BA, Holroyd KJ, Zasloff M. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream[J]. Clin Infect Dis, 2008, 47(12): 1537-1545.
|
| [16] |
Levin M, Quint PA, Goldstein B, et al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group[J]. Lancet, 2000, 356(9234): 961-967.
|
| [17] |
Domingues MM, Santos NC, Castanho MA. Antimicrobial peptide rBPI21: a translational overview from bench to clinical studies[J]. Curr Protein Pept Sci, 2012, 13(7): 611-619.
|
| [18] |
Kang SJ, Park SJ, Mishig-Ochir T, et al. Antimicrobial peptides: therapeutic potentials[J]. Expert Rev Anti Infect Ther, 2014, 12(12): 1477-1486.
|
| [19] |
Fritsche TR, Rhomberg PR, Sader HS, et al. Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections[J]. J Antimicrob Chemother, 2008, 61(5): 1092-1098.
|
| [20] |
Trotti A, Garden A, Warde P, et al. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy[J]. Int J Radiat Oncol Biol Phys, 2004, 58(3): 674-681.
|
| [21] |
Giles FJ, Rodriguez R, Weisdorf D, et al. A phase Ⅲ，randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy[J]. Leuk Res, 2004, 28(6): 559-565.
|
| [22] |
Elad S, Epstein JB, Raber-Durlacher J, et al. The antimicrobial effect of Iseganan HCl oral solution in patients receiving stomatotoxic chemotherapy: analysis from a multicenter, double-blind, placebo-controlled, randomized, phase Ⅲ clinical trial[J]. J Oral Pathol Med, 2012, 41(3): 229-234.
|
| [23] |
Kollef M, Pittet D, Sánchez García M, et al. A randomized double-blind trial of iseganan in prevention of ventilator-associated pneumonia[J]. Am J Respir Crit Care Med, 2006, 173(1): 91-97.
|
| [24] |
Gordon YJ, Romanowski EG, McDermott AM. A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs[J]. Curr Eye Res, 2005，30(7)：505-515.
|
| [25] |
de Sá PB, Havens WM, Ghabrial SA. Characterization of a novel broad-spectrum antifungal protein from virus-infected Helminthosporium (Cochliobolus) victoriae[J]. Phytopathology, 2010, 100(9): 880-889.
|
| [26] |
Zheng R, Yao B, Yu H, et al. Novel family of antimicrobial peptides from the skin of Rana shuchinae[J]. Peptides, 2010, 31(9): 1674-1677.
|
| [27] |
Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies[J]. Nat Biotechnol, 2006, 24(12): 1551-1557.
|
| [28] |
Mygind PH, Fischer RL, Schnorr KM, et al. Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus[J]. Nature, 2005, 437(7061): 975-980.
|
| [29] |
Brandelli A. Nanostructures as promising tools for delivery of antimicrobial peptides[J]. Mini Rev Med Chem, 2012, 12(8): 731-741.
|
| [30] |
Yount NY, Yeaman MR. Emerging themes and therapeutic prospects for anti-infective peptides[J]. Annu Rev Pharmacol Toxicol, 2012, 52: 337-360.
|
| [31] |
Niu Y, Wang RE, Wu H, et al. Recent development of small antimicrobial peptidomimetics[J]. Future Med Chem, 2012, 4(14): 1853-1862.
|
| [32] |
Olsen CA. Peptoid-Peptide hybrid backbone architectures[J]. Chembiochem, 2010, 11(2): 152-160.
|
| [33] |
Méndez-Samperio P. Peptidomimetics as a new generation of antimicrobial agents: current progress[J]. Infect Drug Resist, 2014, 7: 229-237.
|
| [34] |
Werneburg M, Zerbe K, Juhas M, et al. Inhibition of lipopolysaccharide transport to the outer membrane in Pseudomonas aeruginosa by peptidomimetic antibiotics[J]. Chembiochem, 2012, 13(12): 1767-1775.
|
| [35] |
Srinivas N, Jetter P, Ueberbacher BJ, et al. Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa[J]. Science, 2010, 327(5968): 1010-1013.
|
| [36] |
Tillotson GS, Theriault N. New and alternative approaches to tackling antibiotic resistance[J]. F1000Prime Rep, 2013, 5: 51.
|